Accueil   Diary - News   All news GeNeuro Presents Data Supporting Role of Human Endogenous Retroviruses (HERVs) in Type 1 Diabetes

GeNeuro Presents Data Supporting Role of Human Endogenous Retroviruses (HERVs) in Type 1 Diabetes

  • Data presented suggest pathogenic HERV-W envelope (Env) protein to be potential causal factor in Type 1 diabetes
  • Significant expression of pathogenic HERV-W Env found in pancreas of over 50% of Type 1 diabetes patients
  • GNbAC1, a humanized mAb targeting HERV-W Env, currently in Phase 2 study in Type 1 diabetes

 

 

 

12 June 2017 - 7:30am CEST - GeNeuro S.A. (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurological disorders and autoimmune diseases, announced today data supporting the link between human endogenous retroviruses (HERVs) and Type 1 diabetes (T1D). Data were presented at the 77th Scientific Sessions of the American Diabetes Association in San Diego, USA (June 9-13, 2017).

 

 

HERVs are ancestral, pro-viral, genetic elements, currently estimated to account for 8% of the human genome. Most HERVs are repressed, however in certain susceptible individuals, under pathological conditions, they can be transactivated and the resulting viral proteins appear to play a causal role in several autoimmune and neurodegenerative diseases.

 

Read the press release

 

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree